You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Summary• Overall population• HRQoL endpo<strong>in</strong>ts were consistent with efficacy outcomes <strong>in</strong>IPASS• EGFR M+ population• Improvement rates <strong>in</strong> HRQoL and symptoms significantlyfavored gefit<strong>in</strong>ib over C/P• Times to worsen<strong>in</strong>g of HRQoL and symptoms were substantiallylonger for gefit<strong>in</strong>ib than C/P• Median time to improvement <strong>in</strong> HRQoL and symptoms were asrapid as 8 days with gefit<strong>in</strong>ib <strong>in</strong> patients who improved• EGFR M- population• Improvement rates <strong>in</strong> HRQoL and symptoms significantlyfavored C/P over gefit<strong>in</strong>ib• Times to worsen<strong>in</strong>g for HRQoL and symptoms were longer forC/P than gefit<strong>in</strong>ibThongprasert et al. ELCC 2010; Abstract 205O
Change language